Amneal Pharmaceuticals, Inc.

NasdaqGS:AMRX 株式レポート

時価総額：US$4.7b

Amneal Pharmaceuticals 将来の成長

Future 基準チェック /46

Amneal Pharmaceuticals利益と収益がそれぞれ年間41.4%と7.1%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に107.9% 38.8%なると予測されています。

主要情報

41.4%

収益成長率

38.83%

EPS成長率

Pharmaceuticals 収益成長14.7%
収益成長率7.1%
将来の株主資本利益率107.92%
アナリストカバレッジ

Low

最終更新日03 Jun 2026

今後の成長に関する最新情報

Recent updates

ナラティブの更新 • Jun 04

AMRX: Biosimilar Execution And 2026 Outlook Will Support Share Rebound

Analysts have inched their fair value estimate for Amneal Pharmaceuticals up from $17.00 to $17.20 and raised the price target to $16.00, citing stronger confidence in the fiscal 2026 outlook, a solid Q1 update, and an increasing focus on biosimilar opportunities compared with peers. Analyst Commentary Bullish Takeaways Bullish analysts point to the recent Q1 report as a key support for their higher fair value estimates, viewing the current execution as consistent with their fiscal 2026 expectations.
ナラティブの更新 • May 04

AMRX: 2026 EBITDA Outlook Will Support Rebound After GRx Driven Pullback

Amneal Pharmaceuticals' consensus analyst price target has shifted to $17.00, with analysts citing solid Q4 results, strengthened FY26 EBITDA guidance and a reset future P/E assumption as support for this updated view. Analyst Commentary Recent research has focused on how Amneal Pharmaceuticals' updated FY26 guidance and Q4 performance feed into valuation, growth expectations and execution risk around that new US$17.00 price target.
Seeking Alpha • Apr 21

Amneal: A Robust Drug Portfolio Worth Watching, Driving Further Upside Potential

Summary Amneal Pharmaceuticals, Inc. remains a Buy, driven by robust top-line growth, a diversified drug pipeline, and macro demand in key clinical areas. AMRX's FY2025 revenue grew 8% to $3.02B, with positive FY26 guidance and outperformance of Crexont and Brekiya drugs supporting the growth thesis. Despite negative equity and below-investment grade credit, AMRX's 15.2% operating cash flow growth and undervaluation versus peers helps support a bullish outlook. Key risks include drug trial failures, regulatory setbacks, and litigation, but AMRX's pipeline diversification and macro tailwinds across clinical areas bolster its medium-to-long-term potential. Read the full article on Seeking Alpha
ナラティブの更新 • Apr 19

AMRX: 2026 EBITDA Plan And Inhalation Entry Will Drive Bullish Setup

Amneal Pharmaceuticals' analyst price target has shifted from $16.80 to about $17.17, with analysts pointing to recent target increases to $17 following solid Q4 results, 2026 EBITDA guidance strength, and a still intact long term growth thesis as key support for the updated view. Analyst Commentary Recent Street research around Amneal Pharmaceuticals has been concentrated on Q4 results, the new 2026 outlook, and how these feed into revised targets near $17.
ナラティブの更新 • Apr 02

AMRX: 2026 EBITDA Plan And Affordable Medicines Theme Will Drive Bullish Setup

Analysts have raised their price targets on Amneal Pharmaceuticals from $15 to $17, citing solid Q4 results, 2026 guidance that highlights stronger EBITDA expectations, and continued interest in the affordable medicines theme as key supports for the updated view. Analyst Commentary Analysts raising targets to $17 are largely focused on how Amneal executes against its 2026 plan and how that ties into the affordable medicines theme and EBITDA outlook.
ナラティブの更新 • Mar 18

AMRX: 2026 EBITDA Guidance Will Shape Bullish Setup Despite Recent Pullback

Narrative Update on Amneal Pharmaceuticals The analyst price target for Amneal Pharmaceuticals has been revised higher from $16.40 to $16.80. Analysts point to stronger FY26 EBITDA guidance and recent target increases to $17 at multiple firms as support for the updated view.
ナラティブの更新 • Mar 04

AMRX: 2026 EBITDA Outlook And Index Adds Will Shape Bullish Setup

Analysts have lifted their price target on Amneal Pharmaceuticals from $15.20 to $16.40, citing recent target hikes to $17 following solid Q4 results and 2026 guidance. The guidance highlights stronger EBITDA expectations despite more tempered revenue and margin assumptions, along with a higher future P/E of about 50x.
ナラティブの更新 • Feb 17

AMRX: Affordable Medicines Theme And Index Adds Will Shape Measured 2026 Setup

Analysts have nudged their price targets on Amneal Pharmaceuticals higher, with the updated fair value estimate moving from $14.40 to $15.20. This change is supported by recent Street research highlighting continued interest in affordable medicines and the company's role in that theme.
ナラティブの更新 • Feb 03

AMRX: Affordable Medicines Theme And Index Adds Will Shape Balanced 2026 Outlook

Analysts recently lifted their price target on Amneal Pharmaceuticals to $15 from $14, citing the company’s exposure to the affordable medicines theme as a key factor supporting their updated view. Analyst Commentary Recent commentary around Amneal Pharmaceuticals centers on its role in the affordable medicines theme and how that ties into expectations for execution and valuation heading into 2026.
ナラティブの更新 • Jan 19

AMRX: Affordable Medicines Theme And Q3 Execution Will Guide Fairly Balanced Outlook

Narrative Update Analysts have lifted their implied price target on Amneal Pharmaceuticals to about $14.40 from $14, reflecting higher Street targets of up to $15 and supportive views on both the affordable medicines theme and the company’s recent Q3 results versus expectations. Analyst Commentary Recent research updates focus on Amneal Pharmaceuticals' role in affordable medicines and the implications of its latest quarterly results for valuation and execution.
ナラティブの更新 • Jan 05

AMRX: Complex Generics Pipeline And Recent EPS Beat Will Shape Outlook

Analysts have nudged their fair value estimate for Amneal Pharmaceuticals higher to US$14.00 from US$13.80, reflecting updated price targets and recent quarterly results that came in ahead of prior Street EPS and revenue estimates. Analyst Commentary Bullish Takeaways Bullish analysts highlight that Q3 adjusted diluted EPS of US$0.17 came in ahead of prior Street expectations of US$0.14, which they see as a sign of solid execution against current earnings targets.
ナラティブの更新 • Dec 13

AMRX: Complex Generics Approvals Will Support Future Earnings Upside

Analysts have modestly raised their price target on Amneal Pharmaceuticals to approximately $13.80 from about $13.50, reflecting better than expected earnings and revenue performance in the latest quarter. Analyst Commentary Bullish Takeaways Bullish analysts highlight the earnings beat, with adjusted diluted EPS exceeding Street expectations, as evidence that management is executing effectively on cost control and product mix.
分析記事 • Nov 30

Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Price Is Right But Growth Is Lacking After Shares Rocket 25%

Despite an already strong run, Amneal Pharmaceuticals, Inc. ( NASDAQ:AMRX ) shares have been powering on, with a gain...
ナラティブの更新 • Nov 29

AMRX: Continued Execution and Pipeline Milestones Will Support Balanced Outlook

Analysts have raised their price target for Amneal Pharmaceuticals from $11 to $13, citing the company's stronger than expected third-quarter results and improved earnings outlook. Analyst Commentary Following the recent quarterly results, analysts have weighed in on Amneal Pharmaceuticals with a focus on both the company's strengths and areas for caution as they consider the revised price target.
ナラティブの更新 • Nov 15

AMRX: Sustained Outperformance Will Drive Future Earnings Confidence

Analysts have increased their price target for Amneal Pharmaceuticals from $11 to $13. They cite the company’s better-than-expected third-quarter earnings and revenue performance as the reason for this adjustment.
分析記事 • Nov 14

Amneal Pharmaceuticals' (NASDAQ:AMRX) Earnings May Just Be The Starting Point

Amneal Pharmaceuticals, Inc. ( NASDAQ:AMRX ) recently posted some strong earnings, and the market responded positively...
ナラティブの更新 • Nov 01

AMRX: Recent FDA Approvals And Pipeline Launches Will Drive Upside Momentum

Amneal Pharmaceuticals’ analyst price target has risen from $12.67 to $13.50, as analysts cite stronger revenue growth and an improved earnings outlook following the company’s recent results. Analyst Commentary Recent analyst updates indicate a mix of optimism and caution following Amneal Pharmaceuticals’ latest quarterly performance and forward guidance.
ナラティブの更新 • Sep 17

Global Health Trends And Pipeline Launches Will Fuel Future Potential

Amneal Pharmaceuticals' consensus price target has been raised as analysts now assign a higher future P/E multiple, increasing their fair value estimate from $12.00 to $12.67. What's in the News Amneal received FDA approval for its sodium oxybate oral solution 500 mg/mL (generic for Xyrem) for narcolepsy, expanding beyond prior limited authorized generic distribution.
分析記事 • Aug 08

Results: Amneal Pharmaceuticals, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

It's been a good week for Amneal Pharmaceuticals, Inc. ( NASDAQ:AMRX ) shareholders, because the company has just...
分析記事 • Jul 24

Why Investors Shouldn't Be Surprised By Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Low P/S

With a price-to-sales (or "P/S") ratio of 0.9x Amneal Pharmaceuticals, Inc. ( NASDAQ:AMRX ) may be sending very bullish...
User avatar
新しいナラティブ • Mar 22

CREXONT And Metsera Partnerships Will Capitalize On Growing GLP-1 Market

The strategic collaboration in GLP-1 therapies and biosimilars expands market reach, poised to drive significant future revenue growth.
Seeking Alpha • Mar 19

Amneal Pharmaceuticals: Shares Still Feel Significantly Undervalued

Summary Amneal Pharmaceuticals, Inc. seems fundamentally undervalued, with a market cap significantly lower than peers despite similar revenue levels, suggesting potential for substantial stock price appreciation. The company reported strong 2024 financials, with revenues up 17% year-on-year, and forecasts continued growth in 2025, driven by diverse product segments. Amneal is reducing debt effectively, targeting a net debt to EBITDA ratio of 3.6-3.7 in 2025, enhancing financial stability and investor confidence. Key growth areas include biosimilars, specialty drugs like CREXONT, and the high-growth GLP-1 weight loss market, positioning AMRX stock for long-term success. Read the full article on Seeking Alpha
分析記事 • Feb 17

There's No Escaping Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Muted Revenues

With a price-to-sales (or "P/S") ratio of 0.9x Amneal Pharmaceuticals, Inc. ( NASDAQ:AMRX ) may be sending very bullish...
分析記事 • Nov 10

Revenues Working Against Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Share Price

Amneal Pharmaceuticals, Inc.'s ( NASDAQ:AMRX ) price-to-sales (or "P/S") ratio of 1x might make it look like a buy...

業績と収益の成長予測

NasdaqGS:AMRX - アナリストの将来予測と過去の財務データ ( )USD Millions
日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数
12/31/20283,5893475544425
12/31/20273,3391923503865
12/31/20263,107872003755
3/31/20263,046122188306N/A
12/31/20253,01972226340N/A
9/30/20252,9356237328N/A
6/30/20252,8533262351N/A
3/31/20252,830-13233307N/A
12/31/20242,794-117220295N/A
9/30/20242,680-184229313N/A
6/30/20242,598-175176252N/A
3/31/20242,495-169124201N/A
12/31/20232,394-84276346N/A
9/30/20232,38610137186N/A
6/30/20232,312-2114199N/A
3/31/20232,272-135-584N/A
12/31/20222,212-130-2565N/A
9/30/20222,139-13253152N/A
6/30/20222,122-13480140N/A
3/31/20222,0982161214N/A
12/31/20212,09411189242N/A
9/30/20212,06714219285N/A
6/30/20212,0589176247N/A
3/31/20211,987-17408478N/A
12/31/20201,99391313379N/A
9/30/20201,88062183222N/A
6/30/20201,739-194283317N/A
3/31/20201,679-19971159N/A
12/31/20191,626-362N/A2N/A
9/30/20191,727-339N/A312N/A
6/30/20191,825-67N/A234N/A
3/31/20191,834-69N/A115N/A
12/31/20181,663-21N/A250N/A
9/30/20181,459155N/A56N/A
6/30/20181,237149N/A67N/A
3/31/20181,083168N/A192N/A
12/31/20171,034168N/A234N/A
9/30/20171,03954N/A205N/A
12/31/20161,018207N/A115N/A
12/31/2015866169N/A105N/A

アナリストによる今後の成長予測

収入対貯蓄率: AMRXの予測収益成長率 (年間41.4% ) は 貯蓄率 ( 3.5% ) を上回っています。

収益対市場: AMRXの収益 ( 41.4% ) はUS市場 ( 17.9% ) よりも速いペースで成長すると予測されています。

高成長収益: AMRXの収益は今後 3 年間で 大幅に 増加すると予想されています。

収益対市場: AMRXの収益 ( 7.1% ) US市場 ( 12.5% ) よりも低い成長が予測されています。

高い収益成長: AMRXの収益 ( 7.1% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: AMRXの 自己資本利益率 は、3年後には非常に高くなると予測されています ( 107.9 %)。

成長企業の発掘

7D

1Y

7D

1Y

7D

1Y

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/06/10 19:24
終値2026/06/10 00:00
収益2026/03/31
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Amneal Pharmaceuticals, Inc. 5 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。20

アナリスト機関
Glen SantangeloBarclays
Gary NachmanBMO Capital Markets Equity Research
David BuckB. Riley Securities, Inc.